PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Non- Interventional Study EXCALIBUR
Schulz, F.; Hauch, U.; Ketzler-Henkel, S.; von der Heyde, E.; Koenigsmann, M.; Lauseker, M.; Schulte, N.; Germing, U. Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR. J. Clin. Med.2023, 12, 6569.
Schulz, F.; Hauch, U.; Ketzler-Henkel, S.; von der Heyde, E.; Koenigsmann, M.; Lauseker, M.; Schulte, N.; Germing, U. Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR. J. Clin. Med. 2023, 12, 6569.
Schulz, F.; Hauch, U.; Ketzler-Henkel, S.; von der Heyde, E.; Koenigsmann, M.; Lauseker, M.; Schulte, N.; Germing, U. Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR. J. Clin. Med.2023, 12, 6569.
Schulz, F.; Hauch, U.; Ketzler-Henkel, S.; von der Heyde, E.; Koenigsmann, M.; Lauseker, M.; Schulte, N.; Germing, U. Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR. J. Clin. Med. 2023, 12, 6569.
Abstract
Myelodysplastic syndromes and myeloproliferative neoplasms both represent hematologic diseases associated with bone marrow failure often resulting in anemia. For those patients, transfusion of red blood cell (RBC) units is essential, but results in iron overload (IOL) that may affect various organ functions. Therefore, iron chelation therapy plays a major role in anemic patients, not only because it reduces IOL, but also because it may improve hematopoietic function by increasing hemoglobin or diminishing requirement of RBC transfusions. To assess the utility, efficacy and safety of the different iron chelation medication approved in Germany as well as to examine the effect of chelation on hematopoietic insufficiency, a prospective, multicenter, non-interventional study named EXCALIBUR was designed. In total, 502 patients from 106 German hospitals and medical practices were enrolled. A large proportion of patients switched from deferasirox dispersible tablet to deferasirox film-coated tablet, mainly due to more convenient application which was reflected in the treatment satisfaction questionnaire for medication scores. Iron chelation was effective in lowering serum ferritin levels, with the observed adverse drug reactions being in line with the known safety profile. Hematologic response occurred in a few patients, comparable to other studies that examined hematologic improvement in patients with MDS.
Keywords
iron chelation; iron overload; myelodysplastic syndromes; MDS; myeloproliferative neoplasms; MPN; ferritin; hematologic improvement
Subject
Medicine and Pharmacology, Hematology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
